-
Uncategorized3 months agoThe next generation of CAR-T cell therapies
Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space. ...
-
Endpoints News3 months ago
Lessons from the last health tech revolution
Given his former role as US national coordinator for health IT, you might expect that Farzad Mostashari would be an AI enthusiast. But his experience overseeing...
-
Endpoints News3 months ago
FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiong
The FDA warned California-based ImmunityBio for a TV advertisement and podcast that gave the “misleading impression” that Anktiva, the company’s treatment for a type of bladder...
-
Fierce Biotech3 months ago
Icon, Advarra partnership aims to optimize trials, expand access
Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials.
-
Endpoints News3 months ago
Karyopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failure
Plus, news about Aardvark Therapeutics, RA Capital, Gilead and EpiFrontier: 📊 Karyopharm’s late-phase myelofibrosis data: The company’s drug selinexor achieved one co-primary endpoint but missed on...
-
Endpoints News3 months ago
Q&A: Controversial embryo editing entrepreneur Cathy Tie on her new startup
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening...
-
BioPharma Dive – AI / Data3 months ago
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are...
-
STAT News – Biotech3 months agoSTAT+: Can you spot a deepfake X-ray? Neither can your radiologist
Deepfake images can mislead viewers, upend elections, and instigate violence. They can also, researchers say, disrupt medical care. In a study published Tuesday in Radiology, an...
-
BioPharma Dive – AI / Data3 months agoImmutrin raises $87M to advance drug for progressive heart disease
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer,...
-
BioPharma Dive – AI / Data3 months agoKaryopharm myeloma drug yields mixed data in myelofibrosis trial
Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s estimates, could triple the...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
